Nicotinic receptor antagonists as treatments for nicotine abuse

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 513-551

  Crooks, Peter A ^a   Bardo, Michael T ^b   Dwoskin, Linda P ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b University of Kentucky   (United States)

Author keywords

Nicotine analogs; Nicotine dependence; Nicotinic receptor antagonists; Relapse; Smoking cessation

Indexed keywords

ALPHA CONOTOXIN MII; AMFEBUTAMONE; AMMONIUM DERIVATIVE; BIS QUATERNARY AMMONIUM DERIVATIVE; CYTISINE; DOPAMINE; MECAMYLAMINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; QUATERNARY AMMONIUM DERIVATIVE; TETRAKIS QUATERNARY AMMONIUM DERIVATIVE; TRIS QUATERNARY AMMONIUM DERIVATIVE; UNCLASSIFIED DRUG; VARENICLINE;

ARTICLE; DOPAMINE RELEASE; DRUG SELECTIVITY; DRUG SENSITIZATION; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 84893195331     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00013-5     Document Type: Chapter

References (127)

1. Albayati Z.A.F., Dwoskin L.P., Crooks P.A. Pharmacokinetics of the novel nicotinic receptor antagonist N, N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metabolism and Disposition 2008, 18:3870-3873.
2. Anand R., Conroy W.G., Schoepfer R., Whiting P., Lindstrom J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. Journal of Biological Chemistry 1991, 266:11192-11198.
3. Arroyo-Jimenez M.M., Bourgeois J.P., Marubio L.M., Le Sourd A.M., Ottersen O.P., Rinvik E., et al. Ultrastructural localization of the α4-subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. Journal of Neuroscience 1999, 19:6475-6487.
4. Ayers J.T., Dwoskin L.P., Deaciuc A.G., Grinevich V.P., Zhu J., Crooks P.A. bis-Azaaromatic quaternary ammonium analogues: Ligands for α4β2 and α7* subtypes of neuronal nicotinic receptors. Bioorganic and Medicinal Chemistry Letters 2002, 12:3067-3071.
5. Bacher I., Wu B., Shytle D.R., George T.P. Mecamylamine-A nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opinion on Pharmacotherapy 2009, 10:2709-2721.
6. Benowitz N.L. Pharmacology of nicotine: Addiction, smoking-induced disease and therapeutics. Annual Review of Pharmacology and Toxicology 2009, 49:57-71.
7. Bourque J., Mendrek A., Dinh-Williams S.L., Potvin S. Neural circuitry of impulsivity in a cigarette craving paradigm. Front Psychiatry 2013, 4:1-9. Article 67.
8. Brunzell D.H. Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype. Nicotine & Tobacco Research 2012, 14:1258-1269.
9. Brunzell D.H., Boschen K.E., Hendrick E.S., Beardsley P.M., McIntosh J.M. Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. Neuropsychopharmacology 2010, 35:665-673.
10. Cachelin A.B., Rust G. β-Subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Archive: European Journal of Physiology 1995, 429:449.
11. Cartier G.E., Yoshikami D., Gray W.R., Luo S., Olivera B.M., McIntosh J.M. A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. Journal of Biological Chemistry 1996, 271:7522-7528.
12. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry 2005, 48:3474-3477.
13. Cohen C., Bergis O.E., Galli F., Lochead A.W., Jegham S., Biton B., et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics 2003, 306:407-420.
14. Collins A.C., Salminen O., Marks M.J., Whiteaker P., Grady S.R. The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handbook of experimental pharmacology 2009, Vol. 192:85-112. Springer, New York, NY.
15. Conroy W.G., Vernallis A.B., Berg D.K. The α5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron 1992, 9:679-691.
16. Corrigall W.A., Franklin K.B.J., Coen K.M., Clarke P.B.S. The mesolimbic dopaminergic system is implicated in the reinforcing properties of nicotine. Psychopharmacology 1992, 107:285-289.
17. Crooks P.A., Ayers J.T., Rui X., Sumithran S.P., Grinevich V.P., Wilkins L.W., et al. Development of subtype-selective nicotinic receptor ligands as receptor antagonists. Bioorganic and Medicinal Chemistry Letters 2004, 14:1869-1874.
18. 3H]dopamine release by pyridine N-substituted nicotine analogues: A new class of nicotinic antagonist. Drug Development Research 1995, 36:71-82.
19. Cui C., Booker T.K., Allen R.S., Grady S.R., Whiteaker P., Marks M.J., et al. The β3 nicotinic receptor subunit: A component of α-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. Journal of Neuroscience 2003, 23:11045-11053.
20. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annual Review of Pharmacology and Toxicology 2007, 47:699-729.
21. DeNoble V.J., Mele P.C. Intravenous nicotine self-administration in rats: Effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology 2006, 184:266-272.
22. Drenan R.M., Grady S.R., Steele A.D., McKinney S., Patzlaff N.E., McIntosh J.M., et al. Cholinergic modulation of locomotion and striatal dopamine release is mediated by α6α4* nicotinic acetylcholine receptors. Journal of Neuroscience 2010, 30:9877-9889.
23. Drenan R.M., Grady S.R., Whiteaker P., McClure-Begley T., McKinney S., Miwa J.M., et al. In vivo activation of midbrain dopamine neurons via sensitized high affinity α6* nicotinic acetylcholine receptors. Neuron 2008, 60:123-136.
24. Drenan R.M., Nashmi R., Imoukhuede P., Just H., McKinney S., Lester H.A. Subcellular trafficking, pentameric assembly and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled α6 and β3 subunits. Molecular Pharmacology 2008, 73:27-41.
25. Dwoskin L.P., Bardo M.T. Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse. Neuropsychopharmacology 2009, 34:244-246.
26. Dwoskin L.P., Crooks P.A. Competitive neuronal nicotinic receptor antagonists: A new direction for drug discovery. Journal of Pharmacology and Experimental Therapeutics 2001, 298:395-402.
27. 3H]-dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites. Life Sciences 1992, 50:PL233-PL237.
28. Dwoskin L.P., Pivavarchyk M., Joyce B.M., Neugebauer N.M., Zheng G., Zhang Z., et al. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. 55th annual Nebraska symposium on motivation: The motivational impact of nicotine and its role in tobacco use 2009, Vol. 55:31-63. Springer, New York, NY. R.A. Bevins, A.R. Caggiula (Eds.).
29. Dwoskin L.P., Smith A.M., Wooters T.E., Zhang Z., Crooks P.A., Bardo M.T. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical Pharmacology 2009, 78:732-743. NIHMS123315.
30. Dwoskin L.P., Sumithran S.P., Zhu J., Deaciuc A.G., Ayers J.T., Crooks P.A. Subtype-selective nicotinic receptor antagonists: Potential as tobacco use cessation agents. Bioorganic and Medicinal Chemistry Letters 2004, 14:1863-1867.
31. Dwoskin L.P., Wilkins L.H., Pauly J., Crooks P.A. Development of a novel class of subtype-selective nicotinic receptor antagonist: Pyridine-N-substituted nicotine analogs. Annals of the New York academy of sciences 1999, Vol. 868. Wiley Dwoskin, New York, NY, (Special Issue). B. Rudy, P. Seeburg (Eds.).
32. Dwoskin L.P., Wooters T.E., Sumithran S.P., Siripurapu K.B., Joyce B.M., Lockman P.R., et al. N, N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: Inhibition of nicotine-induced dopamine release and hyperactivity. Journal of Pharmacology and Experimental Therapeutics 2008, 326:563-576.
33. Etter J.-F. Cytisine for smoking cessation: A literature review and a meta-analysis. Archives of Internal Medicine 2006, 166:1553-1559.
34. Exley R., Clements M.A., Hartung H., McIntosh M.J., Cragg S.J. α6 Containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008, 3:2158-2166.
35. Fagerstrom K., Balfour D.J. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs 2006, 15:107-116.
36. FDA Drug Safety Communication Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm.
37. FDA Public Health Advisory Public health advisory on Chantix http://www.fda.gov/CDER/Drug/early_comm/varenicline.htm.
38. FDA Public Health Advisory FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm169988.htm.
39. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha4 and beta2 subunits and is up-regulated by chronic nicotine treatment. Molecular Pharmacology 1992, 41:31-37.
40. Forsayeth J.R., Kobrin E. Formation of oligomers containing the β3 and β4 subunits of the rat nicotinic receptor. Journal of Neuroscience 1997, 17:1531-1538.
41. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Journal of Pharmacology and Experimental Therapeutics 1999, 288:88-92.
42. Garwood C.L., Potts L.A. Emerging pharmacotherapies for smoking cessation. American Journal of Health-System Pharmacy 2007, 15:1693-1698.
43. George T.P., O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 2004, 25:42-48.
44. Glick S.D., Visker K.E., Maisonneuve J.M. An oral self-administration model of nicotine preference in rats: Effects of mecamylamine. Psychopharmacology 1996, 128:426-431.
45. Goldner F.M., Dineley K.T., Patrick J.W. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit α6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport 1997, 8:2739-2742.
46. Gotti C., Guiducci S., Tedesco V., Corbiolo S., Zanetti L., Moretti M., et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: Primary role of ventral tegmental area α6β2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. Journal of Neuroscience 2010, 30:5311-5325.
47. Gotti C., Moretti M., Clementi F., Riganti F., McIntosh J.M., Collins A.C., et al. Expression of nigrostriatal α6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by β3 subunit gene deletion. Molecular Pharmacology 2005, 67:2007-2015.
48. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends in Pharmacological Sciences 2006, 27:482-491.
49. Grady S.R., Meinerz N.M., Cao J., Reynolds A.M., Picciotto M.R., Changeux J.-P., et al. Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: A function mediated by a different nAChR than dopamine release from striatum. Journal of Neurochemistry 2001, 76:258-268.
50. Grady S.R., Salminen O., Laverty D.C., Whiteaker P., McIntosh J.M., Collins A.C. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochemical Pharmacology 2007, 74:1235-1246.
51. Hajek P., McRobbie H., Myers K. Efficacy of cytisine in helping smokers quit: Systematic review and meta-analysis. Thorax. 2013, 10.1136/thoraxjnl-2012-203035.
52. Hajek P., Stead L.F., West R., Jarvis M., Hartmann-Boyce J., Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews 2013, (8). Art. No. CD003999. 10.1002/1465188458.
53. Harmey D., Griffin P.R., Kenny P.J. Development of novel pharmacotherapeutics for tobacco dependence: Progress and future directions. Nicotine & Tobacco Research 2012, 14:1300-1318.
54. Harvey S.C., Luetje C.W. Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. Journal of Neuroscience 1996, 16:3798-3806.
55. Harvey S.C., Maddox F.N., Luetje C.W. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. Journal of Neurochemistry 1996, 67:1953-1959.
56. Hurt R.D., Krook J.E., Croghan I.T., Loprinzi C.L., Sloan J.A., Novotny P.J., et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. Journal of Clinical Oncology 2003, 21:914-920.
57. Irvin J.E., Hendricks P.S., Brandon T.H. The increasing recalcitrance of smokers in clinical trials II: Pharmacotherapy trials. Nicotine and Tobacco Research 2003, 5:27-35.
58. Jackson K.J., McIntosh J.M., Brunzell D.H., Sanjakdar S.S., Damaj M.I. The role of α6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. Journal of Pharmacology and Experimental Therapeutics 2009, 331:547-554.
59. Johnstone T.B., Hogankamp D.J., Coyne L., Su J., Halliwell R.F., Tran M.B., et al. Modifying quinolone antibiotics yields new anxiolytics. Nature Medicine 2004, 10:31-32.
60. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006, 296:56-63.
61. Kaiser S.A., Soliakov L., Harvey S.C., Luetje C.W., Wonnacott S. Differential inhibition by α-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices. Journal of Neurochemistry 1998, 70:1069-1076.
62. Koelle G.B. Neuromuscular blocking agents. The pharmacological basis of therapeutic 1975, 575-588. MacMillan Publishing Co., New York, NY. L.S. Goodman, A. Gilman (Eds.).
63. Kulak J.M., Nguyen T.A., Olivera B.M., McIntosh J.M. α-Conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. Journal of Neuroscience 1997, 17:5263-5270.
64. Kuryatov A., Lindstrom J. Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Molecular Pharmacology 2011, 79:126-140.
65. Le Foll B., Goldberg S.R. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. TRENDS in Pharmacological Sciences 2005, 26:287-293.
66. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: An update on addictive properties. Handbook of experimental pharmacology 2009, Vol. 192:335-367. Springer, New York, NY.
67. Le Novère N., Zoli M., Changeux J.P. Neuronal nicotinic receptor alpha6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. European Journal of Neuroscience 1996, 8:2428-2439.
68. Lockman P.R., Geldenhuys W.J., Manda V., Thomas F., Crooks P.A., Dwoskin L.P., et al. Carrier mediated transport at the blood-brain barrier for the quaternary ammonium nicotinic receptor antagonist, N, N-dodecyl-bis-picolinium bromide (bPiDDB). Journal of Pharmacology and Experimental Therapeutics 2008, 324:244-250.
69. Lukas R.J. Pharmacological effects of nicotine and nicotinic receptor subtype pharmacological profiles 2007, CRC Press LLC, Boca Raton, FL.
70. Lundahl L.H., Henningfield J.E., Lukas S.E. Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacology, Biochemistry, and Behavior 2000, 66:637-643.
71. McCallum S.E., Collins A.C., Paylor R., Marks M.J. Deletion of the beta2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology 2006, 184:314-327.
72. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annual Review of Physiology 1995, 57:521-546.
73. McIntosh J.M., Plazas P.V., Watkins M., Gomez-Casati M.E., Olivera B.M., Elgoyhen A.B. A novel alpha-conotoxin, PeIA, cloned from Conus pergrandis, discriminates between rat alpha9alpha10 and alpha7 nicotinic cholinergic receptors. Journal of Biological Chemistry 2005, 280:30107-30112.
74. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacology 2006, 70:801-805.
75. Millar N.S., Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56:237-246.
76. Mills E.J., Wu P., Spurden D., Ebbert J.O., Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinence: A systematic review and meta-analysis. Harm Reduction Journal 2009, 6:25.
77. Mineur Y.S., Somenzi O., Picciotto M.R. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007, 52:1256-1262.
78. Moretti M., Mugnaini M., Tessari M., Zoli M., Gaimarri A., Manfredi I., et al. A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Molecular Pharmacology 2010, 78:287-296.
79. Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. Effect of a novel nicotinic receptor antagonist, N, N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine self-administration and hyperactivity in rats. Psychopharmacology 2006, 184:426-434.
80. Papke R.L., Wecker L., Stitzel J.A. Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. Journal of Pharmacology and Experimental Therapeutics 2010, 333:501-518.
81. Paterson N.E., Min W., Hackett A., Lowe D., Hanania T., Caldarone B., et al. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:1455-1464.
82. Perkins K.A. Nicotine self-administration. Nicotine and Tobacco Research 1999, 2:133-137.
83. Picciotto M.R., Kenny P.J. Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harbor Perspectives in Medicine 2013, 3. 10.1101/cshperspect.a012112.
84. Pons S., Fattore L., Cossu G., Tolu S., Porcu E., McIntosh J.M., et al. Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. Journal of Neuroscience 2008, 28:12318-12327.
85. Quarta D., Ciruela F., Patkar K., Borycz J., Solinas M., Lluis C., et al. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology 2007, 32:35-42.
86. Rahman S., Zhang Z., Papke R.L., Crooks P.A., Dwoskin L.P., Bardo M.T. Region-specific effects of the novel nicotinic receptor antagonist N, N'-dodecane-1,12-diyl-bis-3-picolinium bromide (bPiDDB) on the nicotine-induced increase in extracellular dopamine: An in vivo reverse microdialysis study. British Journal of Pharmacology 2008, 153:792-804.
87. Rau K.S., Birdsall E., Hanson J.E., Johnson-Davis K.L., Carroll F.I., Wilkins D.G., et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005, 49:820-830.
88. Rose J.E. Nicotine and non-nicotine factors in cigarette addiction. Psychopharmacology 2006, 184:274-285.
89. Rose J.E. Disrupting nicotine reinforcement from cigarette to brain. Annals of the New York Academy of Sciences 2008, 1141:233-256.
90. Rose J.E. New findings on addiction and treatment. 55th annual Nebraska symposium on motivation: The motivational impact of nicotine and its role in tobacco use 2009, Vol. 55:230-242. Springer, New York, NY. R.A. Bevins, A.R. Caggiula (Eds.).
91. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical Pharmacology and Therapeutics 1994, 56:86-99.
92. Rose J.E., Salley A., Behm F.M., Bates J.E., Westman E.C. Reinforcing effects of nicotine and non-nicotine components of cigarette smoke. Psychopharmacology 2010, 1:1-12.
93. Salminen O., Drapeau J.A., McIntosh J.M., Collins A.C., Marks M.J., Grady S.R. Pharmacology of α-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Molecular Pharmacology 2007, 71:1563-1571.
94. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Molecular Pharmacology 2004, 65:1526-1535.
95. Sanofi Pipeline. (2012). http://en.sanofi-aventis.com/binaries/080212_PDF_Slides_media_tcm28-15767.pdf.
96. Schuh L.M., Schuh K.J., Henningfield J.E. Pharmacologic determinants of tobacco dependence. American Journal of Therapy 1996, 3:335-341.
97. Shahan T.A., Odum A.L., Bickel W.K. Nicotine gum as a substitute for cigarettes: A behavioral economic analysis. Behavioral Pharmacology 2000, 11:71-79.
98. Slemmer J.E., Martin B.R., Damaj M.I. Bupropion is a nicotinic antagonist. Journal of Pharmacology and Experimental Therapeutics 2000, 295:321-327.
99. Smith A.M., Dhawan G.K., Zhang Z., Siripurapu K.B., Crooks P.A., Dwoskin L.P. The novel nicotinic receptor antagonist, N, N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [3H]norepinephrine overflow from rat hippocampal slices. Biochemical Pharmacology 2009, 78:889-897.
100. Smith A.M., Pivavarchyk M., Wooters T.E., Zhang Z., McIntosh J.M., Crooks P.A., et al. Repeated nicotine increases bPiDDB potency to inhibit nicotine-evoked DA release from rat striatum. Biochemical Pharmacology 2010, 80:402-409.
101. Stoker A.K., Markou A. Unraveling the neurobiology of nicotine dependence using genetically engineered mice. Current Opinion in Neurobiology 2013, 23:493-499.
102. Thomas K.H., Martin R.M., Davies N.M., Metcalfe C., Windmeijer F., Gunnel D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink prospective cohort study. British Journal of Medicine 2013, 347:f5704.
103. Toll L., Zaveri N.T., Polgar W.E., Jiang F., Khroyan T.V., Zhou W., et al. AT-1001: A high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology 2012, 37:1367-1376.
104. Turner J.R., Kellar K.J. Nicotinic cholinergic receptors in the rat cerebellum: Multiple heteromeric subtypes. Journal of Neuroscience 2005, 25:9258-9265.
105. VanderVeen J.W., Cohen L.M., Watson N.L. Utilizing a multimodal assessment strategy to examine variations of impulsivity among young adults engaged in co-occurring smoking and binge drinking behaviors. Drug and Alcohol Dependence 2012, 127:150-155.
106. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., et al. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. Journal of Comparative Neurology 1989, 284:314-335.
107. Whiteaker P., Marks M.J., Grady S.R., Lu Y., Picciotto M.R., Changeux J.P., et al. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. European Journal of Pharmacology 2000, 393(1-3):123-135.
108. Whiting P., Lindstrom J. Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:595-599.
109. Wileyto P., Patterson F., Niaura R., Epstein L., Brown R., Audrain-McGovern J., et al. Do small lapses predict relapse to smoking behavior under bupropion treatment?. Nicotine and Tobacco Research 2004, 6:357-366.
110. Wooters T.E., Smith A.M., Pivavarchyk M., Siripurapu K.B., McIntosh J.M., Zhang Z., et al. bPiDI: A novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology 2011, 163:346-357.
111. Wu P., Wilson K., Dimoulas P., Mills E.J. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health 2006, 6:300.
112. Xiao Y., Fan H., Musachio J.L., Wei Z.L., Chellappan S.K., Kozikowski A.P., et al. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Molecular Pharmacology 2006, 70:1454-1460.
113. Xiao Y., Woolverton W.L., Sahibzada N., Yasuda R.P., Kellar K.J. Pharmacological properties of sazetidine-A, a desensitizer of alpha4beta2 nicotinic acetylcholine receptors. Society for Neuroscience-Abstracts 2007, 33:574.6.
114. Yoshimura R.F., Hogenkamp D.J., Li W.Y., Tran M.B., Belluzzi J.D., Whittemore E.R., et al. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 2007, 323:907-915.
115. Zatonski W., Cedzynska M., Tutka P., West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tobacco Control 2006, 15:481-484.
116. Zhang Z., Lockman P.R., Mittapalli R.K., Allen D.D., Dwoskin L.P., Crooks P.A. bis-Pyridinium cyclophanes: Novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorganic and Medicinal Chemistry Letters 2008, 18:5622-5625.
117. Zhang Z., Pivavarchyk M., Subramanian K.L., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters 2010, 20:1420-1423.
118. Zhang Z., Zheng G., Pivavarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A. tetrakis-Azaaromatic quaternary ammonium: Selective neuronal nicotinic receptor antagonists at subtypes that mediate nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters 2008, 18:5753-5757.
119. Zhang Z., Zheng G., Pivavarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Novel bis-, tris-, and tetrakis tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters 2011, 21:88-91.
120. Zheng F., Bayram E., Sumithran S.P., Ayers J.T., Zhan C.G., Schmitt J.D., et al. QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorganic and Medicinal Chemistry 2006, 14:3017-3037.
121. max) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorganic and Medicinal Chemistry 2009, 17:4477-4485.
122. Zheng G., Sumithran S.P., Deaciuc A.G., Dwoskin L.P., Crooks P.A. tris-Azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters 2007, 17:6701-6706.
123. Zheng G., Zhang Z., Lockman P.R., Geldenhuys W.J., Allen D.D., Dwoskin L.P., et al. bis-Azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter. Bioorganic and Medicinal Chemistry Letters 2010, 20:3208-3210.
124. Zheng G., Zhang Z., Pivarvarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A. bis-Azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorganic and Medicinal Chemistry Letters 2007, 17:6734-6738.
125. Zheng F., Zheng G., Deaciuc A.G., Zhan C., Dwoskin L.P., Crooks P.A. Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the α4β2 nicotinic acetylcholine receptor. Journal of Enzyme Inhibition and Medicinal Chemistry 2009, 24:157-168.
126. Zoli M., Lena C., Picciotto M.R., Changeux J.P. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. Journal of Neuroscience 1998, 18:4461-4472.
127. Zwart R., Carbone A.L., Moroni M., Bermudez I., Mogg A.J., Folly E.A., et al. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Molecular Pharmacology 2008, 73:1834-1843.